Karuna Therapeutics Announces KarXT Met Primary Endpoint in Phase 2 Clinical Trial of Acute Psychosis in Patients with Schizophrenia
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Karuna Therapeutics Inc. (KRTX) Climbs 30%
November 19, 2019 10:36 AM ESTKaruna Therapeutics Inc. (NASDAQ: KRTX) Climbs 30%
... MoreKaruna Therapeutics Inc. (KRTX) Halted on LUDP
November 19, 2019 10:18 AM ESTKaruna Therapeutics Inc. (NASDAQ: KRTX) Halted on LUDP
... MoreKaruna Therapeutics Inc. (KRTX) Confirms Proposed 2.6M Share Public Offering of Common Stock
November 18, 2019 4:22 PM ESTKaruna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and pain, today announced that it has commenced an underwritten public offering of 2,600,000... More
Karuna Therapeutics Inc. (KRTX) Halted on LUDP, Up 230%
November 18, 2019 9:53 AM ESTKaruna Therapeutics Inc. (NASDAQ: KRTX) Halted on LUDP, Up 230%
... MoreKaruna Therapeutics Inc. (KRTX) Extends Gain, Up 175%
November 18, 2019 9:47 AM ESTKaruna Therapeutics Inc. (NASDAQ: KRTX) Extends Gain, Up 175%
... MoreKaruna Therapeutics Inc. (KRTX) Climbs 58% After KarXT Meets Primary Endpoint in Phase 2 Clinical Trial of Acute Psychosis in Patients with Schizophrenia
November 18, 2019 7:17 AM ESTKaruna Therapeutics (NASDAQ: KRTX) Climbs 58% After KarXT Meets Primary Endpoint in Phase 2 Clinical Trial of Acute Psychosis in Patients with Schizophrenia
... More